---
schema_version: "secwatch.filing_event.v1"
accession: "0001680367-23-000033"
form_type: "8-K"
ticker: "STTK"
cik: "0001680367"
company_name: "Shattuck Labs, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:24:36.119063+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Shattuck Labs reports Q1 net loss $20.7M; cash $135.5M; clinical milestones on track

## Summary
- Net loss $20.7M ($0.49 per share) vs $24.5M ($0.58 per share) in Q1 2022.
- Cash and investments $135.5M at March 31, 2023, expected to fund operations through year-end 2024.
- R&D expenses $16.7M (down from $19.2M); G&A $5.1M (flat YoY).
- Complete Phase 1A monotherapy data for SL-172154 in PROC to be presented at ASCO June 2023.
- Initial Phase 1B combo data (liposomal doxorubicin) expected mid-2023; mirvetuximab combo trial dosed first patients.

## SEC filing metadata
- accession: 0001680367-23-000033
- form_type: 8-K
- ticker: STTK
- cik: 0001680367
- company_name: Shattuck Labs, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680367/000168036723000033/0001680367-23-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680367/000168036723000033/sttk-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001680367-23-000033
- JSON: https://secwatch.observer/filing/0001680367-23-000033.json
- Plain text: https://secwatch.observer/filing/0001680367-23-000033.txt

## Key facts
- Earnings Releases
  Shattuck Labs, Inc. reported financial results for the quarter ended March 31, 2023.
  - Period: the quarter ended March 31, 2023
  - Result: reported results
  source text: On May 9, 2023, Shattuck Labs, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680367/000168036723000033/0001680367-23-000033-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.